Effect of angiotensin converting enzyme (ACE) gene polymorphisms on ACE activity before and after ACE inhibition therapy (enalapril) in dogs with mitral valve disease
Degenerative mitral valve disease is the most common heart disease affecting dogs. Affected dogs often develop congestive heart failure after an asymptomatic period. Providing early medical therapy may postpone heart failure, but there is little consensus on the best therapy. We have discovered that some dogs have a genetic variation that results in a less effective response to certain medications. If so, they may need different doses or possibly different medications entirely. We will evaluate a very common medication (enalapril) for this disease in dogs—with and without the genetic variant—that have mitral valve disease and use the information to determine the best cardiac treatment doses for all dogs in the future.
We will need to take a small blood sample from your dog to test for a genetic variation. If the genetic variation is present, we may ask to draw one other blood sample when you return for your reevaluation. The second blood sample will help us determine if the genetic variation effects blood levels of the drug that your dog is on for its heart disease.
- 20 Asymptomatic dogs with myxomatous mitral valve disease and cardiac enlargement (10 with the polymorphisms and 10 without)
- Small blood draw at baseline and 10-14 days after starting therapy with enalapril
There is no cost for participation in this study but if your dog does have the genetic variation we will be able to pay for a blood pressure measurement and blood test (renal profile) as recommended by the cardiologist at your reevaluation.
NCSU Cardiology at 919-513-6694
Page last updated October 28, 2013